Stock EQL EQL PHARMA AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials EQL Pharma AB

Equities

EQL

SE0005497732

Drug Retailers

End-of-day quote NORDIC GROWTH MARKET
Other stock markets
 06:00:00 2024-05-13 pm EDT 		5-day change 1st Jan Change
40 SEK +0.76% Intraday chart for EQL Pharma AB -8.88% +19.76%
Apr. 22 EQL Pharma AB Announces Mellozzan Launched in Germany and Austria CI
Feb. 13 EQL Pharma AB Provides Sales Guidance for the Year 2023/24 CI

Valuation

Fiscal Period: March 2023 2024 2025 2026
Capitalization 1 1,087 1,163 - -
Enterprise Value (EV) 1 1,087 1,229 1,248 1,196
P/E ratio 35.3 x 55.7 x 16.3 x 13 x
Yield - - - -
Capitalization / Revenue - 4.65 x 2.73 x 2.37 x
EV / Revenue - 4.65 x 2.93 x 2.44 x
EV / EBITDA - 29.2 x 11.4 x 8.99 x
EV / FCF - -15.3 x 73.4 x 23.4 x
FCF Yield - -6.55% 1.36% 4.27%
Price to Book - 5.52 x 4.12 x 3.6 x
Nbr of stocks (in thousands) 29,064 29,064 - -
Reference price 2 37.40 40.00 40.00 40.00
Announcement Date 5/11/23 5/14/24 - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2023 2024 2025 2026
Net sales 1 - 264.2 426.2 490
EBITDA 1 - 42.16 109.9 133
EBIT 1 - 32.62 96.3 119
Operating Margin - 12.35% 22.59% 24.29%
Earnings before Tax (EBT) 1 - 28.6 89.54 112
Net income 1 30.92 22.7 71.32 89
Net margin - 8.59% 16.73% 18.16%
EPS 2 1.060 0.7600 2.455 3.070
Free Cash Flow 1 - -83 17 51
FCF margin - -26.51% 3.99% 10.41%
FCF Conversion (EBITDA) - - 15.47% 38.35%
FCF Conversion (Net income) - - 23.84% 57.3%
Dividend per Share 2 - - - -
Announcement Date 5/11/23 5/14/24 - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2024 Q4 2025 Q1 2025 Q2 2025 Q3 2025 Q4
Net sales 1 78.13 80 86 96 104
EBITDA 1 10.79 15 20 23 29
EBIT 1 8.373 12 17 20 26
Operating Margin 10.72% 15% 19.77% 20.83% 25%
Earnings before Tax (EBT) 1 5.947 10 15 18 24
Net income 1 4.693 8 12 15 19
Net margin 6.01% 10% 13.95% 15.62% 18.27%
EPS 2 0.1600 0.2800 0.4100 0.5100 0.6600
Dividend per Share - - - - -
Announcement Date 5/14/24 - - - -
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: March 2023 2024 2025 2026
Net Debt 1 - 104 85 33
Net Cash position 1 - - - -
Leverage (Debt/EBITDA) - 1.098 x 0.7736 x 0.2481 x
Free Cash Flow 1 - -83 17 51
ROE (net income / shareholders' equity) - 21.1% 28.6% 32.2%
ROA (Net income/ Total Assets) - - - -
Assets 1 - - - -
Book Value Per Share 2 - 7.250 9.710 11.10
Cash Flow per Share - - - -
Capex 1 - 0.15 0.16 -
Capex / Sales - 0.05% 0.04% -
Announcement Date 5/11/23 5/14/24 - -
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Drug Retailers

1st Jan change Capi.
EQL PHARMA AB Stock EQL Pharma AB
+19.76% 107M
WALGREENS BOOTS ALLIANCE, INC. Stock Walgreens Boots Alliance, Inc.
-29.72% 15.83B
JD HEALTH INTERNATIONAL INC. Stock JD Health International Inc.
-22.89% 12.31B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED Stock Alibaba Health Information Technology Limited
-24.53% 6.59B
YIFENG PHARMACY CHAIN CO., LTD. Stock Yifeng Pharmacy Chain Co., Ltd.
+15.23% 6.45B
MATSUKIYOCOCOKARA & CO. Stock MatsukiyoCocokara & Co.
-12.43% 5.94B
NAHDI MEDICAL COMPANY Stock Nahdi Medical Company
-0.15% 4.66B
CORPORATIVO FRAGUA, S.A.B. DE C.V. Stock Corporativo Fragua, S.A.B. de C.V.
+62.00% 4.59B
CLICKS GROUP LIMITED Stock Clicks Group Limited
-5.94% 3.96B
DASHENLIN PHARMACEUTICAL GROUP CO., LTD. Stock DaShenLin Pharmaceutical Group Co., Ltd.
-9.36% 3.55B
Other Drug Retailers
  1. Stock Market
  2. Equities
  3. EQL Stock
  4. Financials EQL Pharma AB
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW